Skip to main content
WWB
NASDAQ Life Sciences

Windward Bio Closes $251.2M IPO and Sanofi Placement at $17.00

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$30.04
Mkt Cap
$1.743B
52W Low
$18.35
52W High
$33.985
52W Position info
64% above low
Off High info
12% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

WWB sits 64% above its 52-week low of $18.35 on light trading volume (0.3× avg).

Summary

Windward Bio closed its IPO and a concurrent Sanofi private placement, raising $251.2 million gross at $17.00 per share. The capital funds the pipeline but adds roughly 15.8 million shares to a base of 66.2 million.


Key Events · Financing and Capital Events · WWB

  • IPO and Sanofi Placement Close

    IPO of 11,838,234 shares at $17.00 raised $201.2 million, including full exercise of the 1,544,117-share option; Sanofi bought 1,532,691 shares and pre-funded warrants for 1,408,485 shares for $50.0 million.

  • Dilution From New Shares

    13,370,925 shares plus 1,408,485 pre-funded warrants were sold, about 15.8 million new shares against 66,203,183 outstanding per the new articles — roughly 24% share-count growth.

  • New Articles Effective November 14

    Amended articles set a capital range of CHF 893,742.975 to CHF 1,489,571.610 and conditional capital of 13,240,636 shares for participation programs and 19,860,954 shares for financings and acquisitions.

  • Sanofi as Strategic Holder

    Sanofi Foreign Participations B.V. bought at the $17.00 IPO price, aligning a large pharma partner with public investors.


Analysis · WWB · Life Sciences

Windward Bio completed its Nasdaq IPO and a concurrent private placement to Sanofi on the same day, bringing in $251.2 million gross ($201.2 million from 11,838,234 IPO shares including the full greenshoe, plus $50.0 million from 1,532,691 shares and pre-funded warrants for 1,408,485 shares sold to Sanofi at the same $17.00 price). The cash removes near-term financing risk for a clinical-stage biotech, and Sanofi buying at the IPO price alongside public investors is a meaningful endorsement of the pipeline. The trade-off is dilution: the 13,370,925 shares sold plus 1,408,485 pre-funded warrants equal roughly 15.8 million new shares against 66,203,183 shares outstanding per the new articles — about 24% growth in the share count. The amended articles also give the board a capital range up to CHF 1,489,571.610 and conditional capital of 13,240,636 and 19,860,954 shares, so future issuance capacity is large.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, WWB was trading at $30.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $18.35 to $33.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

WWB - Latest Insights

WWB
Nov 16, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $30.04
Real-time Price: $27.14 info
Change: -$2.90 (-10%) info
Market Cap: $1.575B info
WWB
Nov 12, 2026, 6:19 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: N/A
Real-time Price: $27.14 info
Change: N/A info
Market Cap: $1.575B info